Basic information

Biomarker: CA125

Histology type: endometrial carcinoma

Cohort characteristics

Country: Japan

Region: Tokorozawa

Followed up time :

Subgroup 1 name : positive

Subgroup 1 number: 368

Subgroup 2 name: negative

Subgroup 2 number: 117

Total number Group I Group I number Group II Group II number Group III Group III number Group IV Group IV number
485 endometrial carcinoma

Sample information

Conclusion: Mesothelin expression and co-expression might be associated with tumor aggressiveness and poor prognosis in patients with endometrial carcinoma. Persons with mesothelin-expressing endometrial cancers present a particularly high medical unmet need.

Sample type : tissue

Sample method: immunohistochemistry

Expression pattern : Co-Expression of Mesothelin ( ≥50% (proportion score 3+) and the entire circumference of the cancer cell membrane is stained (intensity score 2+))and CA125 (The percentage of CA125-positive cells is ≥50% (proportion score 3+) and the cytoplasm of cancer cell is highly stained (intensity score 2+))

Expression elevation: The tumor proportion score, defined as the percentage of mesothelin-positive cells in carcinoma tissues, was as follows:0, no tumor cells stained in the entire carcinoma tissue; 1+, ≥1 to < 10% of cells stained in the entire carcinoma tissue; 2+, ≥10 to < 50% of cells stained in the entire carcinoma tissue; and 3+, ≥50% of cells stained in the entire carcinoma tissue. The staining intensity score was defined as follows: 0, no tumor cells stained in the entire carcinoma tissue; 1+, incomplete membrane staining and/or faint or barely perceptible cytoplasmic staining detected; and 2+, entire circumference of the cell membrane stained and/or moderate to strong cytoplasmic staining.

Disease information

Statictics: cutoff<60;cutoff>60

Cohort age: 233;252

Subgroup 1 age: 72;99

Subgroup 2 age: 161;153

Related information

Funtion Uniprot: Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.

UniProt ID: Q8WXI7

UniProt Link: https://www.uniprot.org/uniprotkb/Q8WXI7/entry

Molecular function from UniProt:

Tissue specificity from UniProt: Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas.

Subcellular UniProt: #Cell membrane #Membrane #Secreted

Alternative name from UniProt:

Miscellaneous: Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.

Gene name from HGNC: MUC16 (CA125, FLJ14303)

HPA class: Plasma proteins

AlphaFold DB: SMR Q8WXI7

AlphaFold Link: https://swissmodel.expasy.org/repository/uniprot/Q8WXI7?csm=7D5E9A14F70EB90A

Induction: Up-regulated in ovarian cancer cells.

HPA link: https://www.proteinatlas.org/ENSG00000181143-MUC16

Tissue specificity RNA from HPA: Group enriched (adipose tissue, cervix, fallopian tube, salivary gland)

Tissue expression from HPA: Cytoplasmic and membranous expression in glandular cells of cervix, endometrium, fallopian tube, salivary gland and respiratory epithelium.

Single cell type specificity Cell type enhanced (Respiratory ciliated cells, Glandular and luminal cells, Ionocytes, Club cells, Endometrial ciliated cells, Basal respiratory cells)

Immune cell specificity: Not detected in immune cells

Cancer prognostic summary HPA Gene product is not prognostic

Pathology link: https://www.proteinatlas.org/ENSG00000181143-MUC16/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000181143-MUC16/pathology/endometrial+cancer

Expression figure legend: The expression variation of mesothelin and cancer antigen (CA) 125

Expression figure link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034188/figure/Fig1/

Survival figure legend: Progression-free survival (PFS) and overall survival (OS) of patients according to their differences in expression of mesothelin and CA125, and in the co-expression of both mesothelin and CA125.

Survival curve link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034188/figure/Fig2/

OMIM: 606154

OMIM link2: https://www.omim.org/entry/606154

HGNC ID: HGNC:15582

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15582

Visulization